ライフサイエンスコーパス: zoledronic acid

1 ncer patients (ibandronate, pamidronate, and zoledronic acid).

2 d osteoclastogenesis, which was prevented by Zoledronic acid.

3 tically, with comparable efficacy to that of zoledronic acid.

4 vant systemic therapy either with or without zoledronic acid.

5 f CXCR4 was abrogated with the OC inhibitor, zoledronic acid.

6 CLP-induced bone loss was prevented by Zoledronic acid.

7 he utility of the intravenous bisphosphonate zoledronic acid.

8 benefit with the addition of pravastatin and zoledronic acid.

9 d predict the treatment outcomes of adjuvant zoledronic acid.

10 othesis that ibandronic acid was inferior to zoledronic acid.

11 status and menopausal status on efficacy of zoledronic acid.

12 al small GTPases and this was potentiated by zoledronic acid.

13 patients received open-label treatment with zoledronic acid.

14 o evidence of a benefit from the addition of zoledronic acid (0.94 [0.83-1.07]; p=0.323), which trans

15 sphosphonates (1.03 [0.89-1.18]; p=0.724) or zoledronic acid (0.98 [0.82-1.16]; p=0.782).

16 travenous placebo (n = 1,026) or intravenous zoledronic acid 4 mg adjusted for creatinine clearance a

17 ate 90 mg delivered over at least 2 hours or zoledronic acid 4 mg delivered over at least 15 minutes

18 idronate 90 mg over no less than 2 hours, or zoledronic acid 4 mg over no less than 15 minutes every

19 n automated telephone service to intravenous zoledronic acid (4 mg every 21-28 days) or oral clodroni

20 Zoledronic acid (4 mg infused over 15 minutes) is the fi

21 y assigned in a blinded 1:1 ratio to receive zoledronic acid (4 mg intravenously every 4 weeks) or a

22 ations It is recommended that, if available, zoledronic acid (4 mg intravenously every 6 months) or c

23 d to receive either upfront or delayed-start zoledronic acid (4 mg intravenously every 6 months).

24 res more than -2.5 were randomly assigned to zoledronic acid (4 mg intravenously on day 1 only) or pl

25 Zoledronic acid (4 mg) was given for six 3-weekly cycles

26 Patients were randomly assigned to receive zoledronic acid (4 or 8 mg) or placebo every 3 weeks for

27 90 mg intravenously, every 3 to 4 weeks; or zoledronic acid, 4 mg intravenously every 12 weeks or ev

28 ed to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive

29 of age to receive an intravenous infusion of zoledronic acid (5 mg) or placebo at baseline and at 12

30 randomized to receive infusions with either zoledronic acid (5 mg) or placebo, administered at basel

31 Osteoclast inhibition with zoledronic acid (a bisphosphonate) or with denosumab (a

32 The drug zoledronic acid, a bisphosphonate given for prevention o

33 antitumoral and antiosteolytic activities of zoledronic acid, a bisphosphonate inhibitor of osteoclas

34 These data suggest that zoledronic acid, a drug already in clinical use, may be

35 ring peripheral blood mononuclear cells with zoledronic acid, a gammadelta T lymphocyte activating ag

36 pletion enhanced it, even in the presence of zoledronic acid, a potent antiresorptive agent.

37 Zoledronic acid, a potent bisphosphonate, is commonly ad

38 Zoledronic acid, a potent inhibitor of osteoclast activi

39 Zoledronic acid, a third-generation aminobisphosphonate,

40 To determine whether zoledronic acid administered every 12 weeks is noninferi

41 dministered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks.

42 Patients were randomized to receive zoledronic acid administered intravenously every 4 weeks

43 Zoledronic acid administered with chemotherapy resulted

44 resistance when compared with treatment with zoledronic acid alone.

45 Zoledronic acid also significantly improved progression-

46 ated for more than 3 months (272 patients on zoledronic acid and 273 on risedronate), and the prevent

47 is enhanced by aminobisphosphonates such as zoledronic acid and alendronic acid, both of which promo

48 celecoxib, zoledronic acid and docetaxel, or zoledronic acid and celecoxib) improves survival in men

49 nse did not differ significantly between the zoledronic acid and clodronic acid groups for patients r

50 l (SOC + Doc), or standard of care with both zoledronic acid and docetaxel (SOC + ZA + Doc).

51 rugs (docetaxel, zoledronic acid, celecoxib, zoledronic acid and docetaxel, or zoledronic acid and ce

52 animals were treated with the bisphosphonate zoledronic acid and imaged with (64)Cu-RGD to determine

53 predict likelihood of benefit from adjuvant zoledronic acid and merits further investigation as a po

54 The zoledronic acid and placebo groups did not differ signif

55 These agents are the bisphosphonate zoledronic acid and the monoclonal antibody denosumab.

56 wo osteoclast inhibitors, the bisphosphonate zoledronic acid and the RANKL inhibitor osteoprotegerin,

57 rol group) and thrombosis (five of 60 in the zoledronic acid and two of 59 in the control group).

58 The proapoptotic effect of zoledronic acid and zoledronic acid in combination with

59 iously received a standard dosing regimen of zoledronic acid and/or pamidronate disodium.

60 r who previously received 9 or more doses of zoledronic acid and/or pamidronate during the first 10 t

61 fter treatment with the osteoclast inhibitor zoledronic acid, and histologic analysis of Tax(+) mouse

62 ford progeria syndrome received pravastatin, zoledronic acid, and lonafarnib.

63 Moreover, agents targeting bone biology (eg, zoledronic acid, anti-DKK-1 MoAb, anti-B-cell activating

64 te, intravenous pamidronate, and intravenous zoledronic acid are superior to placebo in reducing skel

65 automated telephone service, to receive 4 mg zoledronic acid as an infusion every 3-4 weeks or 1600 m

66 6 weeks of treatment with either intravenous zoledronic acid at 4 mg every 3-4 weeks or oral ibandron

67 were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients w

68 4 bisphosphonate-treated patients-1,462 with zoledronic acid (breast, 490; prostate, 411; myeloma, 21

69 ditional use of one or two drugs (docetaxel, zoledronic acid, celecoxib, zoledronic acid and docetaxe

70 Treatment with anti-sclerostin antibody and zoledronic acid combined increased bone mass and fractur

71 ist bones with erosions was 0.3 +/- 0.75 for zoledronic acid compared with 1.4 +/- 1.77 for placebo (

72 s study was to assess whether treatment with zoledronic acid, compared with placebo, could achieve a

73 The combination of zoledronic acid + cyclophosphamide/topotecan also signif

74 A single infusion of intravenous zoledronic acid decreases bone turnover and improves bon

75 Zoledronic acid decreases the risk for skeletal-related

76 Combinations of pitavastatin with zoledronic acid displayed additive or synergistic effect

77 research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to stan

78 However, zoledronic acid does reduce the development of bone meta

79 ined after discontinuation of alendronate or zoledronic acid, drug holidays after 5 years of alendron

80 A once-yearly infusion of zoledronic acid during a 3-year period significantly red

81 onate, etidronate, ibandronate, risedronate, zoledronic acid, estrogen, parathyroid hormone (1-34), a

82 3 were white [86.5%]), 203 patients received zoledronic acid every 12 weeks (mean [SD] age, 58.6 [11.

83 tate cancer, or multiple myeloma, the use of zoledronic acid every 12 weeks compared with the standar

84 4 weeks group and 47 patients (23.2%) in the zoledronic acid every 12 weeks group (proportional diffe

85 To examine whether zoledronic acid every 12 weeks was noninferior to zoledr

86 els were higher) among patients who received zoledronic acid every 12 weeks.

87 stemic therapy alone (control group) or with zoledronic acid every 3-4 weeks for six doses, then ever

88 one (control group) or with 4 mg intravenous zoledronic acid every 3-4 weeks for six doses, then ever

89 mized (1:1) to receive 4.0 mg of intravenous zoledronic acid every 4 or every 12 weeks with placebo f

90 women were randomized: 200 patients received zoledronic acid every 4 weeks (mean [SD] age, 59.2 [11.1

91 SREs occurred in 44 patients (22.0%) in the zoledronic acid every 4 weeks group and 47 patients (23.

92 ronic acid every 12 weeks was noninferior to zoledronic acid every 4 weeks in patients with metastati

93 A total of 260 patients (29.5%) in the zoledronic acid every 4-week dosing group and 253 patien

94 ents who received intravenous pamidronate or zoledronic acid for a duration of 3.6 years (range, 2.2

95 or genomic profiling is possible, but use of zoledronic acid for more than 1 year may reduce the yiel

96 mpling, lesion size, core number, and use of zoledronic acid for more than 1 year.

97 mpared oral ibandronic acid with intravenous zoledronic acid for the treatment of metastatic breast c

98 We first show that zoledronic acid given at the same time (early prevention

99 Zoledronic acid given by intravenous infusion has been w

100 [HR] 0.92, 95% CI 0.59-1.41), but was in the zoledronic acid group (0.52, 0.36-0.75).

101 h 26 confirmed on central review, all in the zoledronic acid group (1.7%, 95% CI 1.0-2.4).

102 for intention-to-treat analysis: 981 in the zoledronic acid group (555 on intensive chemotherapy, 42

103 safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in

104 ian time to first SRE was 31.9 months in the zoledronic acid group (95% CI, 24.2 to 40.3) and 29.8 mo

105 ups: 493 in the control group and 473 in the zoledronic acid group (adjusted hazard ratio [HR] 0.94,

106 fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001).

107 ction of 28% in deaths from any cause in the zoledronic acid group (P=0.01).

108 f any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a

109 The numbers of deaths--243 in the zoledronic acid group and 276 in the control group--were

110 Cs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the contr

111 nce or death occurred in 377 patients in the zoledronic acid group and 375 of those in the control gr

112 phometric vertebral fracture was 1.6% in the zoledronic acid group and 4.9% in the placebo group over

113 in rates of overall survival of 85.4% in the zoledronic acid group and 83.1% in the control group (ad

114 e randomly assigned and analysed--981 in the zoledronic acid group and 979 in the clodronic acid grou

115 s were infection (five of 60 patients in the zoledronic acid group and six of 59 in the control group

116 hand and wrist erosions was 61% lower in the zoledronic acid group compared with the placebo group (0

117 ized bone edema developed was smaller in the zoledronic acid group compared with the placebo group (3

118 of 3.7 years (IQR 2.9-4.7), patients in the zoledronic acid group had a lower incidence of skeletal-

119 The zoledronic acid group had a mean change in the number of

120 More patients in the zoledronic acid group had renal toxic effects than in th

121 Fewer patients in the zoledronic acid group had vertebral fractures than did t

122 in the clodronic acid group (50 [5%] in the zoledronic acid group vs 88 [9%] in the clodronic acid g

123 tive (85 in the control groups and 99 in the zoledronic acid group) and the remaining tumours were MA

124 es (445 in the control groups and 420 in the zoledronic acid group).

125 in each group (adjusted hazard ratio in the zoledronic acid group, 0.98; 95% confidence interval [CI

126 In the zoledronic acid group, bone marrow was not collected fro

127 In the zoledronic acid group, there were 17 confirmed cases of

128 one documented case of osteonecrosis in the zoledronic acid group.

129 in the ibandronic acid group and 672 in the zoledronic acid group.

130 eriod, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; re

131 the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; haz

132 e proportion with an SRE was reduced in both zoledronic acid groups compared with the placebo group (

133 Fewer participants who received zoledronic acid had clinical vertebral or nonvertebral f

134 versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs (p=0.054).

135 h men who received placebo, men who received zoledronic acid had fewer moderate-to-severe vertebral f

136 Zoledronic acid has not been studied in patients with se

137 Intravenous zoledronic acid has recently been shown to be as effecti

138 in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects i

139 ion of skeletal-related events, showing that zoledronic acid has treatment benefits beyond bone healt

140 In recent years, bisphosphonates such as zoledronic acid have shown efficacy in preventing and de

141 AEs and acute-phase reactions occurred with zoledronic acid; hypocalcemia occurred more frequently w

142 Pitavastatin (IC50 = 0.6-14 muM), zoledronic acid (IC50 = 21-57 muM), risedronate (IC50 >

143 However, zoledronic acid improved IDFS in those who were over 5 y

144 No evidence exists to suggest that zoledronic acid improves survival in men with M1 or M0 d

145 2004 until 2007 followed by two infusions of Zoledronic acid in 2008 and 2009.

146 e proapoptotic effect of zoledronic acid and zoledronic acid in combination with 4-HC on tumor cells

147 active against tumor cells and suggest that zoledronic acid in combination with cytotoxic chemothera

148 f nuclear factor kappa B (RANK) ligand, with zoledronic acid in delaying or preventing skeletal-relat

149 Denosumab was superior to zoledronic acid in delaying or preventing SREs in patien

150 Denosumab was superior to zoledronic acid in delaying time to first on-study SRE (

151 l recommends only intravenous pamidronate or zoledronic acid in light of the use of the time to first

152 fficacy and safety of earlier treatment with zoledronic acid in men with castration-sensitive metasta

153 se findings support immediate treatment with zoledronic acid in patients with newly diagnosed multipl

154 e findings do not support the routine use of zoledronic acid in the adjuvant management of breast can

155 sumab, a RANK-ligand antagonist, compared to zoledronic acid in the prevention of skeletal related ev

156 The data indicate that zoledronic acid, in addition to inhibiting osteoclasts,

157 a study to determine whether treatment with zoledronic acid, in addition to standard adjuvant therap

158 Annual zoledronic acid increases BMD in postmenopausal women, b

159 In vitro, zoledronic acid inhibited neuroblastoma cell proliferati

160 Zoledronic acid inhibited the association of Ras with th

161 sing allocation concealment, to receive 4 mg zoledronic acid intravenously every 3 weeks (n=60), or n

162 Intravenous use of pamidronate and zoledronic acid is associated with most cases.

163 A single 5 mg intravenous infusion of zoledronic acid is non-inferior, possibly more effective

164 Our results suggest that zoledronic acid is preferable to ibandronic acid in prev

165 The optimal dosing interval for zoledronic acid is uncertain.

166 Annual zoledronic acid may be a convenient and effective strate

167 ypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs.

168 is less clear, but recent data suggest that zoledronic acid may modify the course of the disease and

169 estigational bisphosphonates ibandronate and zoledronic acid may offer the advantage of less frequent

170 (HMG)-CoA reductase and the N-bisphosphonate zoledronic acid monohydrate, an inhibitor of protein pre

171 ction in risk of skeletal complications with zoledronic acid must be weighed against potential advers

172 833 patients were randomised 1:1 to receive zoledronic acid (n=416) or risedronate (n=417).

173 id intravenously every 3 weeks (n=60), or no zoledronic acid (n=60), for 1 year concomitant with four

174 aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cell

175 The effects of zoledronic acid on DFS were not affected by oestrogen-re

176 nvestigate the effect of the adjuvant use of zoledronic acid on disease-free survival (DFS) in high-r

177 We studied the effect of zoledronic acid on fracture risk among men with osteopor

178 assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period.

179 controlled trial to evaluate the effects of zoledronic acid on time to first bone metastasis in men

180 e Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture T

181 Most studies evaluated zoledronic acid or clodronate, and data are extremely li

182 intravenous ibandronate), or have completed (zoledronic acid) or are currently in (denosumab) phase I

183 intravenous ibandronate), or have completed (zoledronic acid) or are currently in (denosumab) phase I

184 gic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip

185 nt with the potential anticancer activity of zoledronic acid, overall survival improved independently

186 ncreased by 4.0% +/- 1.0% in men assigned to zoledronic acid (P < .001).

187 ncreased by 0.7% +/- 0.5% in men assigned to zoledronic acid (P = .004).

188 r markers were lower in the men who received zoledronic acid (P<0.05 for both comparisons).

189 the placebo group, a 35% risk reduction with zoledronic acid (P=0.001); the respective rates of a new

190 ccurred infrequently (2.0%, denosumab; 1.4%, zoledronic acid; P = .39).

191 -existing renal impairment were added to the zoledronic acid package insert.

192 Use of zoledronic acid, peripheral sampling, core number, and l

193 results in structural end points in favor of zoledronic acid plus MTX compared with MTX alone.

194 for which he was receiving intravenous (IV) zoledronic acid, presented for routine periodontal maint

195 se, osteoclast inhibition with bone-targeted zoledronic acid protected Tax+ mice from bone and soft-t

196 However, liposomal zoledronic acid proved highly toxic to SCID Beige mice.

197 sults of this study support the early use of zoledronic acid rather than clodronic acid in patients w

198 months after the intravenous bisphosphonate zoledronic acid received regulatory approval for marketi

199 Zoledronic acid reduced mortality by 16% (95% CI 4-26) v

200 Zoledronic acid reduced the development of bone metastas

201 Treatment with zoledronic acid reduced the risk of morphometric vertebr

202 h bone metastases recently demonstrated that zoledronic acid reduces the risk of skeletal-related eve

203 riod, representing a 67% risk reduction with zoledronic acid (relative risk, 0.33; 95% confidence int

204 evaluated combinations of pitavastatin with zoledronic acid, risedronate and GGTI-2133 in a panel of

205 h the potent bisphosphonates pamidronate and zoledronic acid seems to be well tolerated and should be

206 Zoledronic acid showed no evidence of survival improveme

207 ving a GnRH agonist, a single treatment with zoledronic acid significantly increased BMD and durably

208 Additionally, 4 mg zoledronic acid significantly increased time to first ev

209 y (SOC-only; control), standard of care plus zoledronic acid (SOC + ZA), standard of care plus doceta

210 events were more frequent in patients given zoledronic acid than in those on risedronate, largely as

211 risons between clodronate and pamidronate or zoledronic acid, the superiority of one agent cannot be

212 ibandronic acid and 0.435 (0.393-0.480) with zoledronic acid; the rate ratio for skeletal-related eve

213 suggest a structural benefit associated with zoledronic acid therapy in patients with RA, as demonstr

214 5 years of alendronate therapy or 3 years of zoledronic acid therapy may be considered for patients a

215 Synergy Trial (Z-FAST) indicate that upfront zoledronic acid therapy prevents bone loss in the LS in

216 dexamethasone (RVD) plus monthly intravenous zoledronic acid therapy.

217 o receive ibandronic acid and 699 to receive zoledronic acid; three patients withdrew immediately aft

218 The addition of zoledronic acid to adjuvant letrozole therapy may protec

219 l-QoL) in a large randomized trial (Adjuvant Zoledronic Acid to Reduce Recurrence [AZURE]).

220 gest no overall benefit from the addition of zoledronic acid to standard adjuvant treatments for earl

221 aseline characteristics were similar in both zoledronic acid treatment arms.

222 Zoledronic acid treatment was associated with a signific

223 last activity, decreased significantly after zoledronic acid treatment.

224 e FIT trial, 1.50 (95% CI, 0.25 to 9.00) for zoledronic acid use in the HORIZON-PFT trial, and 1.33 (

225 acebo group (38% for 4 mg and 35% for 8/4 mg zoledronic acid v 44% for the placebo group; P =.127 and

226 At 3 months, 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not rec

227 ffectiveness of 5 mg intravenous infusion of zoledronic acid versus 5 mg oral risedronate for prevent

228 study was designed to compare the effects of zoledronic acid versus clodronic acid in newly diagnosed

229 fatigue (97 [14%] of 697 patients allocated zoledronic acid vs 98 [14%] of 704 allocated ibandronic

230 The zoledronic acid was administered every 3 to 4 weeks for

231 Zoledronic acid was also associated with a lower risk of

232 Zoledronic acid was also associated with a significant i

233 In patients with MAF-negative tumours, zoledronic acid was associated with higher invasive-dise

234 eatment-emergent serious adverse events, but zoledronic acid was associated with higher rates of conf

235 at randomisation with MAF-positive tumours, zoledronic acid was associated with lower invasive-disea

236 ractures more than placebo; the evidence for zoledronic acid was fair.

237 Zoledronic acid was non-inferior and superior to risedro

238 o assess whether one intravenous infusion of zoledronic acid was non-inferior to daily oral risedrona

239 The every 12 weeks regimen of zoledronic acid was noninferior to the every 4 weeks reg

240 Early zoledronic acid was not associated with increased time t

241 er and bone metastases, early treatment with zoledronic acid was not associated with lower risk for S

242 The safety profile of zoledronic acid was similar to that of placebo.

243 Proliferation induced by zoledronic acid was used as a surrogate of gammadelta TC

244 Zoledronic acid was well tolerated; the most common adve

245 In mice treated with zoledronic acid, we observed a marked inhibition of oste

246 requent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musc

247 who received bisphosphonates (pamidronate or zoledronic acid) were identified.

248 The delayed group received zoledronic acid when lumbar spine (LS) or total hip (TH)

249 patients with cancer, who were treated with zoledronic acid, who unexpectedly developed osteonecrosi

250 The choice between pamidronate and zoledronic acid will depend on choosing between the high

251 on choosing between the higher drug cost of zoledronic acid, with its shorter, more convenient infus

252 An annual infusion of zoledronic acid within 90 days after repair of a low-tra

253 Zoledronic acid (ZA) 4 mg was administered for six 3-wee

254 Oncology [CALGB/Alliance 70604]) showed that zoledronic acid (ZA) every 3 months was noninferior to m

255 nuclear factor kappa-B ligand antibody, with zoledronic acid (ZA) for delaying or preventing skeletal

256 f clonal and primary oral keratinocytes with zoledronic acid (ZA) inhibited p63, and expression was r

257 Zoledronic acid (ZA) is commonly combined with docetaxel

258 We examined whether zoledronic acid (ZA) prevents bone loss in premenopausal

259 cal MMP inhibitor and with a bisphosphonate, zoledronic acid (ZA), revealing both to be antiangiogeni

260 ontitis (EP) in Wistar-Han rats treated with zoledronic acid (ZA).

261 containing bisphosphonates (N-BP), including zoledronic acid (ZOL) and alendronate (ALD), have been p

262 ells are expanded in vitro after exposure to zoledronic acid (ZOL) and efficiently lyse primary lymph

263 ed induction and maintenance regimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960

264 a-secretase inhibitor (gammaSI), Sirtinol or zoledronic acid (ZOL) in order to enhance the inhibitory

265 onavir + tenofovir/emtricitabine to a single zoledronic acid (ZOL) infusion (5 mg) vs placebo to dete

266 itor (PS-341) and osteoclastic inhibition by zoledronic acid (Zol) on the development of ATLL and HHM

267 Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommende

268 Significant benefits for zoledronic acid (ZOL) over clodronate acid (CLO) were se

269 Nitrogen-bisphosphonates such as zoledronic acid (ZOL) trigger selective gammadelta T cel

270 We hypothesized that the bisphosphonate drug zoledronic acid (ZOL) would inhibit tumor-induced osteol

271 To interfere with the development of SBD, zoledronic acid (Zol), a potent inhibitor of osteoclast

272 osphonate drugs, either alendronate (ALN) or zoledronic acid (ZOL), opened Cx43 hemichannels in osteo

273 patients with early breast cancer, adjuvant zoledronic acid (zoledronate) may reduce recurrence and